Alkem Laboratories Q3 PAT up 16.56% at Rs525.66cr on sharp 20% growth in India revenues

7 Feb 2022 , 07:34 AM

Alkem Laboratories reported growth of 12.98% in sales revenues for the Dec-21 quarter on consolidated basis at Rs2,618.98cr. On a sequential basis, the revenues were lower for the quarter by -6.46%.

During the quarter, Alkem reported 19.9% growth in India sales at Rs1,816cr while international sales were lower by -0.4% at Rs771cr.

R&D expenses in the quarter stood at Rs145cr representing 5.5% of the sales of the company. The portfolio of Alkem benefited from the tailwinds of the COVID pandemic during the Dec-21 quarter.

The consolidated Profit after tax (PAT) for the Dec-21 quarter was up 16.56% at Rs525.66cr. While the EBITDA margins in the quarter actually from 22.8% to 19% yoy, this was more than compensated by the deferred tax benefits in the quarter from the restructuring of its US based subsidiaries, which resulted in higher profits.

Global revenues were a drag on the top line even as the domestic sales made up for it. Net margins improved from 19.45% in the Dec-20 quarter to 20.07% in Dec-21 quarter. Net margins were higher sequentially too.

Financial highlights for Dec-21 compared yoy and sequentially

	Alkem Laboratories
Rs in Crore	Dec-21	Dec-20	YOY	Sep-21	QOQ
Total Income (Rs cr)	₹ 2,618.98	₹ 2,318.05	12.98%	₹ 2,799.99	-6.46%
Net Profit (Rs cr)	₹ 525.66	₹ 450.96	16.56%	₹ 544.26	-3.42%
Diluted EPS (Rs)	₹ 43.96	₹ 37.72		₹ 45.52
Net Margins	20.07%	19.45%		19.44%